Patents by Inventor Sung-Youl Ko

Sung-Youl Ko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10898566
    Abstract: The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 26, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney S. Graham, Theodore C. Pierson, Kimberly A. Dowd, John R. Mascola, Wing-pui Kong, Sung-youl Ko, Eun Sung Yang, Wei Shi, Lingshu Wang, Christina R. Demaso, Rebecca S. Pelc, Adrian Creanga, Julie Ledgerwood, Leda R. Castilho
  • Publication number: 20190374633
    Abstract: The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.
    Type: Application
    Filed: July 28, 2017
    Publication date: December 12, 2019
    Inventors: Barney S. GRAHAM, Theodore C. PIERSON, Kimberly A. DOWD, John R. MASCOLA, Wing-pui KONG, Sung-youl KO, Eun Sung YANG, Wei SHI, Lingshu WANG, Christina R. DEMASO, Rebecca S. PELC, Adrian CREANGA, Julie LEDGERWOOD, Leda R. CASTILHO
  • Publication number: 20190345205
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.
    Type: Application
    Filed: November 15, 2017
    Publication date: November 14, 2019
    Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The United States of America, as Represented by the Department of Health and Human Services
    Inventors: Kimberly DOWD, Barney S. GRAHAM, Sung-Youl KO, Wing-Pui KONG, John MASCOLA, Theodore PIERSON, Mayuri SHARMA, Dong Yu
  • Patent number: 8003093
    Abstract: The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with ?-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: August 23, 2011
    Assignee: Seoul National University Industry Foundation
    Inventors: Chang-Yuil Kang, Yeonseok Chung, Hyun-Jeong Ko, Yeon-Jeong Kim, Byung-Seok Kim, Sung-Youl Ko
  • Publication number: 20100028380
    Abstract: The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with ?-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.
    Type: Application
    Filed: April 27, 2006
    Publication date: February 4, 2010
    Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION
    Inventors: Chang-Yuil Kang, Yeonseok Chung, Hyun-Jeong Ko, Yeon-Jeong Kim, Byung-Seok Kim, Sung-Youl Ko
  • Publication number: 20080317769
    Abstract: The present invention related to a vaccine composition comprising alpha-galactosylceramide (?GalCer) as an adjuvant for the intranasal administration. The present inventors administered ?GalCer together with a tumor cell antigen or a virus antigen to the nasal cavity of a mouse and then confirmed that the ?GalCer effectively induced not only humoral immunity but also cell-mediated immunity. Thus, the ?GalCer can be effectively used as an adjuvant for a vaccine by the intranasal administration for the prevention and treatment of virus infection and cancer.
    Type: Application
    Filed: April 3, 2006
    Publication date: December 25, 2008
    Inventors: Chang-Yuil Kang, Sung-Youl Ko